The Stanford medical school professor, the expected pick for the top job at the National Institutes of Health, has been a ...

New data suggests clinicians may be slower to recognize sepsis in people with pulmonary arterial hypertension.

Paul Fronstin, director of Health Benefits Research at EBRI, spoke with MHE about the challenges employers face in ...

Poor balance and coordination are prominent features of Friedreich’s ataxia (FRDA). Czech researchers found that neuropsychiatric symptoms are also common among patients with FRDA.

ICER to Assess Sanofi’s Tolebrutinib for Secondary Progressive MS ...

Binghamton University, Mayo Clinic and Others Snare NIH Funding for IBD Research ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

Whether this proposed rule actually has any impact remains to be seen, especially with a new administration led by Donald ...

Vutrisiran is the generic form of previously approved Amvuttra. The FDA’s target date for the treatment of transthyretin amyloidosis with cardiomyopathy is March 23, 2025.

For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the ...

Greg Baker, CEO of AffirmedRx, shared with MHE editors how the company is addressing ongoing challenges in the pharmacy ...

The menopause market is projected to increase at a CAGR of 5.10% between 2025 – 2033, with North America making up 4.9% ...